Navigation Links
MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza
Date:9/21/2009

GAITHERSBURG, Md., Sept. 21 /PRNewswire/ -- MedImmune announced today that the U.S. Department of Health and Human Services (HHS) has placed an order for an additional 29 million doses of its live attenuated influenza vaccine (LAIV) against the 2009 H1N1 influenza virus. This brings HHS orders to date to more than 40 million vaccine doses, with a total cumulative contract value of approximately $453 million. Previous HHS orders for approximately 13 million doses of LAIV for the 2009 H1N1 strain were placed in May and July.

The vaccine received approval from the U.S. Food and Drug Administration (FDA) on Sept. 15 and is indicated for the active immunization of individuals 2-49 years of age against influenza caused by pandemic (H1N1) 2009 virus.

MedImmune's development of LAIV for this strain of H1N1 began at the end of April, when the company received the novel virus from the U.S. Centers for Disease Control and Prevention (CDC). Enough bulk vaccine to fill all orders placed by HHS has already been manufactured and about 3.4 million doses have been released by the FDA. Distribution will occur at the direction of public health authorities.

"At MedImmune, our mission is to develop and deliver medicines that change lives, and we are proud that our innovative LAIV technology may help protect the public from the threat of 2009 H1N1 influenza," said Tony Zook, president of MedImmune. "We will continue to work collaboratively with the U.S. government and public health authorities to contribute to the response to this unpredictable infectious disease."

About LAIV

LAIV is different from the injectable influenza vaccine ("flu shot") in that it contains live vaccine virus strains that are weakened so as not to cause the flu. It is delivered into the nose, where the influenza virus usually enters the body, rather than by injection.
'/>"/>

SOURCE MedImmune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics
2. MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
3. Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
4. MedImmune grants 5 new fellowships to help expand premature infant follow-up care research
5. MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
6. MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations
7. MedImmune Expands Scientific and Engineering Leadership
8. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
9. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
10. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
11. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 ... weights, breast milk is more likely than a blood transfusion ... (CMV), a new study finds. The researchers evaluated more ... whom weighed 3.3 pounds or less and many who were ... see whether breast milk or transfusions carried the bigger risk. ...
(Date:9/23/2014)... San Francisco, CA (PRWEB) September 23, 2014 ... search for original 1967 The Doors Eagle Auditorium Seattle concert ... of their album “Break On Through” that year. The Seattle ... According to Hawley, “The Doors would return to Eagles Auditorium ... Doors July poster is not known and comes in three ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- The number of ... drugs is growing, so doctors need to be ... Drug Administration warned Tuesday. In a statement, ... that it has launched a program to educate ... about proper drug purchasing procedures. The program aims ...
(Date:9/23/2014)... Vancouver Electrician Contractors, Pro Ace, has ... electrical services in Vancouver, BC. The company will provide ... a small maintenance project or a large-scale new installation ... meet the needs of the individual commercial client. Pro ... of an affordable price. As a result, businesses of ...
(Date:9/23/2014)... September 23, 2014 The University ... research university located In the Piedmont Triad, announced ... as co-director of the Center for Translational Biomedical ... comes to UNCG after nearly a decade at ... Laboratory, Biological Sciences Division. , “Our goal ...
Breaking Medicine News(10 mins):Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:Former Department of Energy Scientist Joins UNCG as Co-director of Biomedical Research Center 2
... improve the effectiveness of the only tuberculosis vaccine approved ... in a pre-clinical test, report scientists at The University ... Nature Medicine ,s Advance Online Publication March 1. Their ... funded by the National Institutes of Health (NIH). ...
... Medical Event Available from the Convenience of a Computer, www.CardioCareLive.com ... from 9:30 AM to 8:00 PM Eastern.,Patch Adams, MD, the real ... speak. To register now for free, visit cardioCareLive.com. , ... ...
... American Public Health Association,s (APHA) new Fluoridation Position ... support nor evaluate fluoridation,s safety and/or effectiveness as ... Fluoridation, Inc. APHA asserts, "All of these reviews ... safe and effective." Here,s the truth about APHA,s ...
... drug-eluting stentNATICK, Mass., March 3 Boston Scientific ... the launch of its TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary ... approved on January 28 by the Ministry of ... yesterday by the National Health Insurance System.TAXUS Liberte ...
... patients, the soles of their feet and the palms of ... because of some types of chemotherapy. Patients, family members also ... , Both share a need for quick answers or ... diagnosis, treatments, or unexpected symptoms. , A new section ...
... to Defend His TitleNORTHRIDGE, Calif., March 3 There ... names, two decks of shuffled playing cards, or a ... minutes. Chester Santos, the 2008 USA National Memory Champion, ... when he defends his title at the USA National ...
Cached Medicine News:Health News:TB breakthrough could lead to stronger vaccine 2Health News:TB breakthrough could lead to stronger vaccine 3Health News:CardioCareLive, First-Ever Online Cardiometabolic Conference, Debuts Today 2Health News:APHA Misleads Americans About Fluoridation 2Health News:Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System 2Health News:Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System 3Health News:Walther Cancer Foundation grant funds new IU Simon Cancer Center Web site section 2Health News:The Making of a Memory Champion 2Health News:The Making of a Memory Champion 3
(Date:9/23/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a ... diseases and cholesterol gallstones, announced today that the ... approved its request for Fast Track Designation of ... Non-Alcoholic Steato-Hepatitis, or NASH.  FDA ...
(Date:9/23/2014)...  SiteOne Therapeutics Inc. today announced the completion of ... Capital Management and Biobrit LLC, with additional investors Mission ... million financing positions SiteOne to advance its oral Na ... develop its technology platform for long-acting local analgesics, pain ... with the financing, Lowell Sears (Sears Capital ...
(Date:9/23/2014)... Sept. 23, 2014  KemPharm, Inc., a clinical-stage ... development of proprietary new molecular entity (NME) prodrugs, ... Letter (NOL) from Health Canada to begin clinical ... its lead product candidate KP201 (benzhydrocodone hydrochloride and ... for acute moderate to moderately severe pain. The ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3
... PXS) today announced significant results of pooled data from ... of Bronchitol (inhaled mannitol) in people with cystic fibrosis. ... the first time at the North American Cystic Fibrosis ... results from the second trial (CF302) have been released ...
... Oct. 22 INVO Bioscience, Inc. (OTC Bulltin Board: ... for patients diagnosed with infertility, today announced that Dr. ... (CECOFLES LTDA) will present the results of the first ... INVO Bioscience,s INVOcell technology at the 66th Annual Meeting ...
Cached Medicine Technology:Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 2Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 3Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 4Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 5INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine 2INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine 3
Transcranial vascular DWL doppler....
... is an automated system capable of handling ... definition of many of the tests allows ... your patients' and staffs' needs. Any tests ... automated tests can easily be handled using ...
The CD Horizon M10 Spinal System provide spine surgeons comprehensive solutions for the treatment of spinal deformities, trauma reconstruction, and degenerative conditions....
... Neurocare - continues the revolutionary ... Exceptional convenience and speed. Superior Doppler ... delivers features you won't find anywhere ... cuff attachment and testing. Up to ...
Medicine Products: